Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 4;16(2):1-8.
doi: 10.5365/wpsar.2025.16.2.1157. eCollection 2025 Apr-Jun.

Experience conducting COVID-19 vaccine effectiveness studies in response to the COVID-19 pandemic in Japan and the Philippines: lessons for future epidemics and potential pandemics

Takeshi Arashiro  1   2   3   4   5 , Regina Pascua Berba  6 , Joy Potenciano Calayo  7 , Rontgene Solante  8 , Shuichi Suzuki  9 , Jinho Shin  5 , Motoi Suzuki  3 , Martin Hibberd  1 , Koya Ariyoshi  2 , Chris Smith  1   2
Affiliations

Experience conducting COVID-19 vaccine effectiveness studies in response to the COVID-19 pandemic in Japan and the Philippines: lessons for future epidemics and potential pandemics

Takeshi Arashiro et al. Western Pac Surveill Response J. .

Abstract

Problem: Once COVID-19 vaccines were rolled out, there was a need to monitor real-world vaccine effectiveness to accumulate evidence to inform policy and risk communication. This was especially true in Japan and the Philippines, given historical issues that affected vaccine confidence.

Context: Neither country had public health surveillance that could be enhanced to evaluate vaccine effectiveness or readily available national vaccination databases.

Action: Study groups were established in multiple health-care facilities in each country to assess vaccine effectiveness against both symptomatic infection and severe disease.

Outcome: In Japan, multiple study reports were published in Japanese on the web site of the National Institute of Infectious Diseases and presented at the national government's advisory board. Nationwide media coverage facilitated transparency and increased the confidence of the government and the public in the vaccination programme. In the Philippines, the launch of the study was delayed so as to align the research plan with the interests of various stakeholders and to obtain institutional review board approval. Ultimately, the studies were successfully initiated and completed.

Discussion: There were four main challenges in conducting our studies: finding health-care facilities for data collection; obtaining exposure (vaccination) data; identifying epidemiological biases and confounders; and informing policy and risk communication in a timely manner. Preparedness during inter-emergency/epidemic/pandemic periods to rapidly evaluate relevant interventions such as vaccination is critical and should include the following considerations: (1) the establishment and maintenance of prospective data collection platforms, ideally under public health surveillance (if not, clinical research networks or linked databases); (2) uniform and practical protocols considering biases and confounders; and (3) communication with stakeholders including institutional review boards.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Epidemic curves of the number of reported COVID-19 cases and vaccine rollout with study milestones in (A) Japan and (B) the Philippinesa
See this image and copyright information in PMC

References

    1. COVID-19 vaccine effectiveness. Geneva: World Health Organization; 2024. Available from: https://www.who.int/teams/immunization-vaccines-and-biologicals/immunization-analysis-and-insights/surveillance/covid−19-vaccine-effectiveness-and-impact, accessed 1 January 2024.
    1. COVID-19 vaccine trial designs in the context of authorized COVID-19 vaccines and expanding global access: ethical considerations. Geneva: World Health Organization; 2021. Available from: https://www.who.int/publications/i/item/WHO−2019-nCoV-Policy-brief-Vaccine-trial-design−2021.1, accessed 1 January 2024.
    1. Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Duration of protection against mild and severe disease by Covid-19 vaccines. N Engl J Med. 2022. Jan 27;386(4):340–50. 10.1056/NEJMoa2115481 - DOI - PMC - PubMed
    1. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022. Apr 21;386(16):1532–46. 10.1056/NEJMoa2119451 - DOI - PMC - PubMed
    1. Evaluation of COVID-19 vaccine effectiveness: interim guidance. Geneva: World Health Organization; 2021. Available from: https://www.who.int/publications/i/item/WHO−2019-nCoV-vaccine_effectiveness-measurement−2021.1, accessed 1 January 2024.

Substances

LinkOut - more resources